Effects of beraprost sodium and insulin on the electroretinogram, nerve conduction, and nerve blood flow in rats with streptozotocin-induced diabetes

Diabetes

Volumn 45, Issue 3, 1996, Pages 361-366

  Hotta, Nigishi ^a   Koh, Naoki ^a   Sakakibara, Fumihiko ^a   Nakamura, Jiro ^a   Hamada, Yoji ^a   Hara, Tomohiro ^a   Mori, Koichi ^a   Nakashima, Eitaro ^a   Naruse, Keiko ^a   Fukasawa, Hideo ^a   Kakuta, Hironobu ^a   Sakamoto, Nobuo ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; INSULIN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; ELECTRORETINOGRAM; MALE; NERVE CONDUCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RETINA BLOOD FLOW; SCIATIC NERVE; STREPTOZOCIN DIABETES;

EID: 13344282059     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.45.3.361     Document Type: Article

References (57)

1. Little NL: Alterations in blood elements in the pathogenesis of diabetic retinopathy Ophthalmology 88:647-654, 1981
2. Kohner EM: Diabetic retinopathy. Br Med J 307.1195-1199, 1993
3. Vinik AI, Holland MT, LeBeau JM, Liuzzi FJ, Stansberry KB, Colen LB: Diabetic neuropathies. Diabetes Care 15:1926-1975, 1992
4. Cameron NE, Cotter MA: The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 10:189-224, 1994
5. Tesfaye S, Malik R, Ward JD: Vascular factors in diabetic neuropathy. Diabetologia 37:847-854, 1994
6. Gabbay KH: The sorbitol pathway and the complications of diabetes. N Engl J Med 288:831-836, 1973
7. Kador PF: The role of aldose reductase in the development of diabetic complications. Med Res Rev 8:325-352, 1988
8. Ilotta K, Sakamoto N: Aldose reductase inhibitors. In The Diabetes Annual 5. Alberti KGMM, Krall LP, Eds. Amsterdam, Elsevier, 1990, p. 330-361
9. Tomlinson DR: Aldose reductase inhibitors and the complications of diabetes mellitus. Diabetic Med 10:214-230, 1993
10. Greene DA, Lattimer-Greene SA, Sima AAF: Pathogenesis and prevention of diabetic neuropathy. Diabetes Metab Rev 4:201-212, 1988
11. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
12. Baynes JW: Role of oxidative stress in the development of complications in diabetes. Diabetes 40:405-412, 1990
13. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, Tilton RG: Hyperglycemic pseudohypoxia and diabetic complications Diabetes 42.801-813, 1993
14. Yonemura D, Aoki T, Tsuzuki K: Electroretinogram in diabetic retinopathy. Arch Ophthalmol 68 49-54, 1962
15. Algver P: Clinical studies on the oscillatory potentials of the human electroretinogram with special reference to the scotopic b-wave. Acta Ophthalmol 46:993-1024, 1968
16. Simonsen SE. ERG in diabetes. In The Clinical Value of Electroretinography. Francois J, Ed. New York, Karger Basel, 1968, p 403-412
17. Miller RF, Dowling JE: Intracellular responses of the Muller (glial) cells of mudpuppy retina: their relation to the b-wave of the electroretinogram. J Neurophysiol 33:323-341, 1970
18. Karwoski CJ, Proenza LM: Relationship between Müller cell responses, a local transretinal potential, and potassium flux. J Neurophysiol 40:244-259, 1977
19. Kozak WM, Deneault LG, Rogowska J: ERG amplitude and latency changes during early diabetes mellitus in rats (Abstract). Doc Ophthalmol Proc Ser 37:351, 1983
20. Sato S, Sugimoto S, Ando T, Miyajima H, Chiba S: An electrophysiological method for detecting diabetic retinopathy in rats. Folia Pharmacol Jpn 84:500-517, 1984
21. 1 analogue (TFC-612) prevents a decrease in motor nerve conduction velocity in streptozotocin-diabetic rats. Biochem Biophys Res Commun 150:225-230, 1988
22. 1 analogue (TFC-612) improves the reduction in motor nerve conduction velocity in spontaneously diabetic GK (Goto-Kakizaki) rats. Prostaglandins 40:463-471, 1990
23. 2 derivative (iloprost) on peripheral neuropathy of diabetic rats. Diabetes Res Clin Pract 18:123-130, 1992
24. Cotter MA, Dines KC, Cameron NE: Prevention and reversal of nerve dysfunction in streptozotocin-diabetic rats by treatment with the prostacyclin analog iloprost. Naunyn-Schmiedeberg's Arch Pharmacol 347: 534-540, 1993
25. Sim AK, McCraw AP, Cleland ME, Nishio S, Umetsu T: Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation. Arzneim-Forsch 35:1816-1818, 1985
26. Nishio S, Yamada N, Endoh T, Isogai M, Fukatsu Y, Nishimura S, Kanai N, Umetsu T: Effect of beraprost sodium on peripheral circulatory disturbances induced by various stimuli. Arzneim-Forsch 39:1229-1234, 1989
27. Hotta N, Kakuta H, Fukasawa H, Koh N, Sakakibara F, Komori H, Sakamoto N: Effect of niceritrol on streptozocin-induced diabetic neuropathy in rats Diabetes 41:587-591, 1992
28. Segawa M, Hirata Y, Fujimori S, Okada Y. The development of electroretinogram abnormalities and the possible role of polyol pathway activity in diabetic hyperglycemia and galactosemia. Metabolism 37:454-460, 1988
29. Miyoshi T, Goto I: Serial in vivo determinations of nerve conduction velocity in rat tails physiological and pathological changes Electroencephalogr Clin Neurophysiol 35:125-131, 1973
30. Hotta N, Kakuta H, Fukasawa H, Kimura M, Koh N, Iida M, Terashima H, Morimura T, Sakamoto N Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats. Diabetologia 28:176-180, 1985
31. Hotta N, Kakuta H, Fukasawa H, Koh N, Sakakibara F, Nakamura J, Hamada Y, Wakao T, Hara T, Mori K, Naruse K, Nakashima E, Inukai S, Sakamoto N: Effect of a potent new aldose reductase inhibitor, (5-(3-thienyl) tetrazol-1-yl) acetic acid (TAT), on diabetic neuropathy in rats. Diabetes Res Clin Pract 27:107-117, 1995
32. Koshu K, Kamiyama K, Oka N, Endo S, Takaku A, Saito T: Measurement of regional blood flow using hydrogen gas generated by electrolysis. Stroke 13.483-487, 1982
33. Clements RS, Morrison AD, Winegrad AI: Polyol pathway in aorta: regulation by hormones. Science 166:1007-1008, 1969
34. Bernt E, Bergmeyer HU. D-Fructose. In Methods of Enzymatic Analysis. Bergmeyer HU, Ed. New York, Verlag Chemie/Academic, 1974, p. 1304-1307
35. 2. Jpn J Injlamm 7:511-515, 1987
36. Honma M, Satoh T, Takezawa J, Ui M: An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small-volume samples from blood and tissue Biochem Med 18:257-273, 1977
37. McGregor LC, Matschinsky FM: Treatment with aldose reductase inhibitor or with myo-inositol arrests deterioration of the electroretinogram of diabetic rats. J Clin Invest 76:887-889, 1985
38. Kozak WM, Marker NA, Elmer KK: Effects of aldose reductase inhibition on the retina and health indices of streptozotocin-diabetic rate. Doc Ophthalmol 64:355-377, 1986
39. Hotta N, Kakuta H, Fukasawa H, Ando F, Miyake Y, Awaya S, Sakamoto N: Diabetic retinopathy. In Current Status of Prevention and Treatment of Diabetic Complications Sakamoto N, Alberti KGMM, Hotta N, Eds. Amsterdam, Elsevier, 1990, p. 195-205
40. Lowitt S, Malone JI, Salem AI, Kozak WM, Orfalian Z: Acetyl-L-carnitine corrects electroretinographic deficits in experimental diabetes. Diabetes 42:1115-1118, 1993
41. Biersdorf WR, Malone JI, Pavan PR, Lowitt S: Cone electroretinograms and visual acuities of diabetic patients on sorbinil treatment. Doc Ophthalmol 69:247-254, 1988
42. Hotta N, Sakamoto N, Fukuda M, Matsui M, Ando F, Goto Y, Shigeta Y: Epalrestat can truly prevent diabetic retinopathy in clinical double-blind study (Abstract). Diabetes 39 (Suppl. 1):61A, 1990
43. Harrison HE, Reece AH, Johnson M: Decreased vascular prostacyclin in experimental diabetes. Life Sci 23:351-355, 1978
44. Silberbauer K, Schernthaner G, Sinzinger H, Piza-Katzer H, Winter M: Decreased vascular prostacyclin in juvenile onset diabetes. N Enql J Med 300:366-367, 1979
45. Gerrard JM, Stuart MJ, Rao GHR, Steffes MW, Mauer SM, Brown DM, White JG: Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats. J Lab Clin Med 95:950-958, 1980
46. Ward KK, Low PA, Schmelzer ID, Zochodne DW Prostacyclin and noradrenaline in peripheral nerve of chronic experimental diabetes in rats. Brain 112:197-208, 1989
47. 2 mimetics in severe peripheral vascular disease. Biomed Biochim Acta 47:S40-S44, 1988
48. 2) analog, in severe peripheral arterial disease (PAD). Adv Prostaglandin Thromboxane Leukotriene Res 19: 311-316, 1989
49. Mayhan WG, Simmons LK, Shape GM: Mechanism of impaired responses of cerebral arterioles during diabetes mellitus. Am J Physiol 260:H319-H326, 1991
50. Durante W, Sen AK, Sunahara FA: Impairment of endothelium-dependent relaxation in aorta from spontaneously diabetic rats. Br J Pharmacol 94:463-468, 1988
51. Low PA, Lagerlund TD, McManis PG: Nerve blood flow and oxygen delivery in normal, diabetic and ischemic neuropathy. Int Rev Neurobiol 31:355-438, 1989
52. Cameron NE, Cotter MA: Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: evidence from experimental studies Diabetic Med 10:593-605, 1993
53. Tesfaye S, Harris N, Jakubowski J, Mody C, Wilson RM, Rennie IG, Ward JD: Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia 36:1266-1274, 1993
54. Shindo H, Tawata M, Aida K, Onaya T: Clinical efficacy of a stable prostacyclin analog, iloprost, in diabetic neuropathy. Prostaglandins 41:85-96, 1991
55. Shindo H, Tawata M, Onaya T: Regulation of cyclic AMP in the sciatic nerve of rats made diabetic with streptozotocin and the mechanism involved. J Endocrinol 136:431-438, 1993
56. Thiemermann C, Steinhagen-E. Schror K: Inhibition of oxygen-centered free radical formation by the stable prostacyclin-mimetic iloprost (ZK 36 374) in acute myocardial ischemia. J Cardiovasc Pharmacol 6:365-366, 1984
57. Suzuki H, Suematsu M, Ishii H, Kato S, Miki H, Mori M, Ishimura Y, Nishino T, Tsuchiya M: Prostaglandin E1 abrogates early reductive stress and zone-specific paradoxical oxidative injury in hypoperfused rat liver. J Clin Invest 93:155-164, 1994